Biomea Fusion, Inc. (BMEA) Dividend History

Company News

• Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

  The retinal and fundus camera market is experiencing growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). The integration of artificial intelligence (AI) into fundus cameras presents a significant opportunity for market growth, with AI algorithms demonstrating high accuracy in detecting diseases like diabetic retinopathy (DR).

  GlobeNewswire Inc.

  Featured Companies: BLCO EYEN OTLK
• Biomea Fusion Announces Leadership Transition

  Biomea Fusion, a clinical-stage diabetes and obesity medicines company, announced that Mick Hitchcock, a current board member, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately.

  GlobeNewswire Inc.
• Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

  Biomea Fusion, a clinical-stage biopharmaceutical company, will host a conference call to present topline results from its Phase II trial of icovamenib in patients with type 2 diabetes.

  GlobeNewswire Inc.
• Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

  Biomea Fusion announced that the World Health Organization (WHO) and the United States Adopted Name Council have approved 'icovamenib' as the International Nonproprietary Name and United States Adopted Name for its lead product candidate BMF-219, which is an oral covalent menin inhibitor in clinical development for diabetes.

  GlobeNewswire Inc.
• FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

  Biomea Fusion announced that the FDA has lifted the clinical hold on its ongoing Phase I/II trials of BMF-219 in type 2 and type 1 diabetes. The company is encouraged by the safety review and looks forward to continuing the development of BMF-219.

  GlobeNewswire Inc.